1396 related articles for article (PubMed ID: 22301066)
1. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
2. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.
Varma R; Bressler NM; Suñer I; Lee P; Dolan CM; Ward J; Colman S; Rubio RG;
Ophthalmology; 2012 Oct; 119(10):2108-18. PubMed ID: 22817833
[TBL] [Abstract][Full Text] [Related]
3. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
4. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
7. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
Thach AB; Yau L; Hoang C; Tuomi L
Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
[TBL] [Abstract][Full Text] [Related]
13. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
Bhisitkul RB; Campochiaro PA; Shapiro H; Rubio RG
Ophthalmology; 2013 May; 120(5):1057-63. PubMed ID: 23415775
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
17. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab and retinal vein occlusion. Too many outstanding questions.
Prescrire Int; 2012 Sep; 21(130):207. PubMed ID: 23016250
[TBL] [Abstract][Full Text] [Related]
19. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]